Analysts/Institutional Investor Meet/Con. Call Updates

05th November 2026 National Stock Exchange of India Ltd. BSE Limited Exchange Plaza, Plot no. C/1, G Block, Phiroze Jeejeebhoy Towers, Bandra-Kurla Complex, Bandra (E) Dalal Street Mumbai - 400 051 Mumbai – 400 001 Security Symbol: IOLCP Security Code: 524164 Subject: Transcript of Earnings Call on Q2 & H1 FY27 Financial Results Dear Sir, Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the transcript of the Earnings Call on the financial performance of the Company for the Q2 & H1 FY27 held on Monday, 02nd November 2026: You are requested to take the same on records. Thanking You, Yours faithfully, For IOL Chemicals and Pharmaceuticals Limited Abhay Raj Singh Sr. Vice President & Company Secretary “IOL Chemicals and Pharmaceuticals Limited Q2 and H1 FY27 Earnings Conference Call” November 02, 2026 MANAGEMENT: MR. PARDEEP KUMAR KHANNA – CHIEF FINANCIAL OFFICER – IOL CHEMICALS AND PHARMACEUTICALS LIMITED MR. ABHAY RAJ SINGH – SENIOR VICE PRESIDENT AND COMPANY SECRETARY– IOL CHEMICALS AND PHARMACEUTICALS LIMITED MR. KUSHAL KUMAR RANA – DIRECTOR WORKS – IOL CHEMICALS AND PHARMACEUTICALS LIMITED MR. RAKESH MAHAJAN – FINANCIAL ADVISOR AND STRATEGIC HEAD – IOL CHEMICALS AND PHARMACEUTICALS LIMITED MODERATOR: MR. VAIBHAV VIJAYWARGIYA – MUFG INVESTOR RELATIONS Page 1 of 19 IOL Chemicals and Pharmaceuticals Limited November 02, 2026 Moderator: Ladies and gentlemen, good day. and welcome to IOL Chemicals and Pharmaceuticals Limited Q2 and H1 FY27 Earnings Conference Call. As a reminder, all participant lines will be in the listen-only mode, and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during this conference call, please signal an operator by pressing star then zero on your touchtone phone. Please note that this conference is being recorded. I now hand the conference over to Mr. Vaibhav Vijaywargiya from MUFG Investor Relations. Thank you and over to you, sir. Vaibhav Vijaywargiya: Thank you, Huda. Good morning, everyone, and welcome to Q2 and H1 FY27 Earnings Call of IOL Chemicals and Pharmaceuticals Limited. Joining us today are Mr. Pardeep Kumar Khanna, who is the Chief Financial Officer, Mr. Abhay Raj Singh, who is Senior Vice President and Company Secretary, Mr. Kushal Kumar Rana, Director Works, and Mr. Rakesh Mahajan, who is the Financial Advisor and Strategic Head to provide the results overview recently announced by the company. Before we begin the call, I would like to give a short disclaimer. This call may contain some of the forward-looking statements which are completely based upon our beliefs and expectations as of today. These statements are not a guarantee of our future performance and involve unforeseen risk and uncertainties. With this, I would now like to hand over the call to Mr. Abhay sir for his opening remarks. Over to you, sir. Thank you. Abhay Raj Singh: Thank you, Vaibhav. Good morning, everyone, and welcome to the Q2 and H1 FY27 earnings conference call of IOL Chemicals and Pharmaceuticals Limited. Thank you for joining us today and for your continued trust and support. I hope you have had an opportunity to review our financial results and investor presentations filed with the stock exchanges and available on our website. We have maintained the positive momentum during the second quarter of FY27, delivering healthy growth across our businesses, accompanied by a meaningful improvement in profitability. This performance is particularly encouraging in the backdrop of continued geopolitical uncertainties, global supply chain disruptions, and volatility in raw material prices. It reflects the benefits of our continued focus on product mix, operational efficiencies, better capacity utilization, and disciplined execution of our business strategy. Coming to our pharmaceuticals business, we continue to witness encouraging demand across our product portfolio. Our non-ibuprofen portfolio maintained its growth momentum, registering approximately 70% Y-o-Y revenue growth during Q2 and contributing 45% of pharmaceutical revenue, compared with 38% in the corresponding quarter last year. This reflects the increasing scale and contributions of our diversified API portfolio. At the same time, ibuprofen continues to remain an important business for IOL and we remain focused on strengthening our competitive position through capacity expansion, backward integration, and process efficiencies. Our chemicals business also witnessed a significant Page 2 of 19 IOL Chemicals and Pharmaceuticals Limited November 02, 2026 improvement in performance with its contributions to overall EBIT increasing to approximately 7% during Q2, compared with around 1% in the corresponding quarter last year. This improvement reflects better realization, operating efficiencies, and disciplined procurement. We believe our integrated manufacturing capabilities and investments in capacity enhancements will further strengthen this business and support its contribution to the company's overall performance. On the regulatory front, we achieved important milestone during the quarter. We received certificate of suitability from EDQM for Fenofibrate-Process II, taking our total CEP approvals to 22. Additionally, we received a GMP certification for our formulation CDMO facility, further strengthening our regulatory credentials and manufacturing capabilities. During the quarter, we also secured EU-REACH registrations for our triacetin, strengthening our ability to access international markets. These developments represent important steps towards expanding our regulated market presence, enhancing our manufacturing capabilities, and creating opportunities for sustainable growth across our pharmaceuticals and specialty chemicals portfolio. Moving to our strategic growth initiatives, during the quarter, we announced three significant manufacturing projects involving a combined investment of approximately INR500 crores to be funded through internal accruals. These projects represent an important step in strengthening our manufacturing platform and broadening our business portfolio. The initiatives include the expansion of our ibuprofen manufacturing capacity from 12,000 MTPA to 18,000 MTPA through a backward integrated facility, establishment of a formulation CDMO facility with an annual capacity of 1,500 million tablets or equivalent direct compressible grade volume, and setting up a dedicated specialty chemicals facility under a long-term tolling arrangement with a leading global chemical company. These investments are aligned with our long-term objective of building scale, strengthening integration, and creating additional growth avenues. The CDMO and specialty chemical projects are expected to commence commercial operations during FY27, while the ibuprofen expansion is targeted for commissioning in FY28. Our CDMO initiative will enable us to leverage our existing pharmaceutical manufacturing and process capabilities to participate in a broader range of customer requirements. Similarly, the specialty chemical projects is aimed at establishing our presence in contract manufacturing, providing an opportunity to develop long-term engagement with global customers and create an additional avenue for growth. Together, these initiatives will broaden our revenue streams and strengthen our position across the pharmaceutical and specialty chemicals value chain. Looking ahead, our priorities remain focused on executing the announced capital projects, scaling our diversified API portfolio, improving operating efficiencies, and strengthening our presence in international markets. We will continue to pursue growth opportunities with a disciplined approach to capital allocation while maintaining a strong focus on operational excellence and financial performance. The progress achieved during the first half of FY27 reinforces our conf [Showing first 8,000 characters — download PDF for full document]